Emcure Pharmaceuticals Limited (EMCURE) — Announcement | 12 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Chairman Berjis Desai retired to assume government role while Satish Mehta took additional Chairman duties and Samit Mehta appointed COO
🔄 What Changed
Chairman retirement, new COO appointment, Gennova stake acquisition to 100% subsidiary
🔮 What's Next
FY27 revenue growth of low to mid-teens and EBITDA margin expansion of 70-100 bps
💡 Investor Takeaway
Shareholders gain confidence in growth trajectory through international expansion and strategic leadership changes post-restructuring

Emcure Pharmaceuticals reported strong Q1 FY27 results with 22.8% YoY revenue growth to INR 2,580 crore and 36.2% YoY PAT growth to INR 292 crore, driven by international expansion (34.2% growth) and resilient domestic growth (10.2%). Chairman Berjis Desai retired from the board to take a government role, while Satish Mehta assumed additional Chairman duties post-AGM and Samit Mehta was appointed new COO. The company acquired a 12.05% stake in Gennova, making it a 100% subsidiary. Management highlighted pipeline progress including 15+ approvals, anti-HPV and HIV licensing deals, and biosimilars focus under Samit Mehta's leadership, with FY27 revenue growth guidance of low to mid-teens and EBITDA margin expansion of 70-100 bps.

📄 View Original Announcement (PDF)

About Emcure Pharmaceuticals Limited (EMCURE)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹35,011.16 Cr P/E: 34.6 ROE: 22.9% ROCE: 29.7% Div Yield: 0.20%

View full EMCURE stock details →

📡 Get AI alerts when EMCURE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track EMCURE — Free

📊 More EMCURE filings

See all EMCURE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when EMCURE files new disclosures

Track EMCURE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track EMCURE — Free

Free account · 2 AI queries/day